Arax Advisory Partners’s ALX Oncology ALXO Stock Holding History

Arax Advisory Partners’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2	Closed	-$3	–	4093
2025 Q3	$3	Buy	+2	New	+$2	﹤0.01%	3600

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arax Advisory Partners's ALXO Position: Q4 2025 in Review

Arax Advisory Partners sold out of ALX Oncology (ALXO) in Q4 2025, closing a stake of 2 shares — an estimated $3 sold.

Arax Advisory Partners first reported a position in ALXO in Q3 2025 and held it in 1 quarter. The position peaked at $3 in Q3 2025. 57 funds tracked by Wall St. Rank hold ALXO as of Q4 2025.

Arax Advisory Partners reported no remaining ALX Oncology position as of Q4 2025 after selling out during the quarter.
Arax Advisory Partners sold 2 ALX Oncology shares in Q4 2025, an estimated $3.
Arax Advisory Partners first reported a position in ALX Oncology in Q3 2025 and held it in 1 quarter.
Arax Advisory Partners's ALX Oncology position peaked at $3 in Q3 2025.
57 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.